Bonti 2018-05-03T16:36:06+00:00

Blazing New Paths
For Life Enhancing Treatments

Our BoNT/E product candidates

Our pipeline is comprised of two BoNT/E product candidates. Our therapeutic product candidate, EB-001T, is being developed for the treatment of focal muscle pain, localized pain that can be caused by muscle contractions and spasms, for which there are currently no approved therapies. Our aesthetic product candidate, EB-001A, is being initially developed for glabellar frown lines and scar reduction following Mohs micrographic surgery, or Mohs surgery.

News and Information

Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain

May 9th, 2018|

Follows Completion of LANTERN-1 Clinical Trial Bonti, Inc., an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications, today announced it has initiated dosing in its LANTERN-2 clinical trial, a Phase 2 clinical trial under Bonti’s LANTERN (Long-Acting [...]

Bonti Announces Scientific Presentation at Premier Aesthetic Plastic Surgery Conference

April 25th, 2018|

EB-001T and EB-001A To Be Spotlighted at The Aesthetic Meeting 2018 Bonti, Inc., an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications, today announced a Hot Topics presentation for its therapeutic product candidate, EB-001T, and for its aesthetic [...]

Bonti Appoints Dr. Jacob Chacko to Board of Directors

February 12th, 2018|

Bonti, a privately-held, clinical-stage biotechnology company, today announced the appointment of Dr. Jacob Chacko to its Board of Directors, effective immediately. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. (NASDAQ: RXDX) since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications, [...]

Read Articles